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plasia（BPH/LUTS）1）. As improvement of symptoms 
occurs relatively early after administration, a1-block-
ers are considered to be extremely beneficial. Howev-
er, some patients respond poorly to these drugs need 
additional medications. In recent years, a combination 
of an a1-blocker and a 5-alpha reductase inhibitor 
has been shown to relieve BPH/LUTS better than 
monotherapy with each compound, especially in 
patients with a large prostate 2）. Furthermore, some 
trials have demonstrated the efficacy and safety of a 
combination of an a1-blocker and an anticholinergic 
????????????
An alpha 1-adrenoceptor blocker（a1 blocker）has 
been widely used for the treatment of lower urinary 
tract symptoms suggestive of benign prostatic hyper-
Dokkyo Journal of Medical Sciences
??（1 ：17 〜 23，2017
????????
Efficacy of Tadalafil Add-on Treatment for Men with 
Lower Urinary Tract Symptoms Refractory to Alpha-1 
Adrenoceptor Blockers
Hiroshi Yagi, M.D., Gaku Arai, M.D., Shigehiro Soh, M.D., Hiroshi Okada, M.D.
Department of Urology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan
???????
????????????：To evaluate the efficacy and safety of once daily phosphodiesterase type 5 inhibitor
（PDE5i）tadalafil as an add-on treatment for men with lower urinary tract symptoms suggestive of benign 
prostatic hyperplasia（BPH/LUTS）refractory to an alpha 1-blocker（a1-blocker）. 
?????????????????????：This study enrolled men aged ＞50 years with BPH/LUTS and erectile dys-
function（ED）that were refractory to ＞3 months of a1-blocker. We defined “refractory” as an internation-
al prostate symptoms score（IPSS）of ＞8 and a maximum flow rate（Qmax）＜15 despite in no space take 
of an a1-blocker. Patients with contraindications to phosphodiesterase-5 inhibitors；those with symptoms 
of other diseases that were difficult to differentiate from BPH/LUTS；and those with postvoid residual of 
＞100 ml were excluded. Eligible patients received added-on treatment with tadalafil 5 mg/day for 12 
weeks. 
???????：Tadalafil add-on treatment significantly improved the IPSS parameters in terms of total score
（P＜0.001）, subscore for storage（P＝0.001）, subscore for voiding（P＜0.001）, and quality of life（P＝0.002）. 
The 3-day frequency volume chart showed significant improvements in mean number of daily nocturnal 
micturations（P＝0.002）, nocturnal polyuria index（P＝0.001）, and hours of undisturbed sleep（P＝0.006）. 
Five patients dropped out because of an adverse event：two with a headache, two with dizziness and one 
with dyspepsia. There were no serious adverse events. 
??????????：Tadalafil add-on treatment was effective for patients with BPH/LUTS and ED that were 
resistant to a1-blockers.
????????： tadalafil, benign prostatic hyperplasia, lower urinary tract symptoms, refractory to alpha-1 
adrenoceptor blockers
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agent for BPH/LUTS patients with significant symp-
toms of urinary retention and overactive bladder
（OAB）3,4）.
There had been basic scientific evidence that BPH/
LUTS and erectile dysfunction（ED）share the same 
pathophysiology 5〜7）. Oger et al. demonstrated in vitro 
that a combination of an a1-blocker and a phosphodi-
esterase-5 inhibitor（PDE5i）was more efficient than 
each compound alone in relaxing the adrenergic tone 
or enhancing the nitrergic relaxation of the human 
corpus cavernosum 8）. However, existing clinical trials 
of a combination of an a 1-blocker and a PDE5 i 
reported a variety of outcomes with inconsistent find-
ings 9〜10）. Furthermore, other data suggested that a 
combination of an a 1-blocker and a PDE5i might 
worsen hemodynamic changes 10）.
To clarify the efficacy and safety of a combination 
of an a1-blocker and a PDE5i, we performed a sin-
gle-center prospective study of once daily PDE5i 
tadalafil add-on treatment in patients with BPH/
LUTS and ED that were resistant to a1-blockers.
?????????????????????
This open label study was designed as a prospec-
tive investigation. The study protocol was approved 
by the Ethics Committee of Dokkyo Medical Universi-
ty Koshigaya Hospital（#1406）, and was conducted in 
compliance with the Helsinki Declaration. We obtained 
written informed consent from all participants after 
thoroughly explaining the efficacy and possible 
adverse reactions of a combination of an a1-blocker 
and tadalafil.
The inclusion criteria were men aged ＞50 years；a 
total International Prostate Symptom Score（IPSS）of 
≥ 8 points despite treatment with a1-blockers for at 
least 3 months；bladder outlet obstruction as indicated 
by a maximum urinary flow rate（Qmax）of £ 15 ml/
s；and self-reported ED as indicated by an Interna-
tional Index of Erectile Function of Erectile Function 
Domain（IIEF5）of £ 11 points. Exclusion criteria were 
history of specified contraindications to PDE5i；pros-
tate-specific antigen（PSA）＞10 ng/ml or ＞4 ng/ml if 
prostate cancer could not be ruled out；post void 
residual urine volume（PVR）of ＞100 ml；and the 
presence of other diseases that caused symptoms that 
were difficult to differentiate from those of BPH/
LUTS.
Patients had been receiving an a1-blocker（either 
tamsulosin 0.2 mg/day or naftopidil 50 mg/day）until 
the day of study enrollment（day 0）. After enrollment, 
once daily tadalafil 5 mg was prescribed in addition to 
an a1-blocker for 12 weeks. During the study period, 
patients were asked to refrain from using other medi-
cations that influenced urinary frequency and inconti-
nence, as well as drugs that produce nitric oxide.
The efficacy of treatment was assessed using the 
data collected from a questionnaire and 3-day fre-
quency volume chart（FVC）before and after the 
treatment period. IPSS and IIEF5 were determined 
by a physician（HY）who was blinded on the clinical 
background of the patients. Other efficiency variables 
included Qmax, PVR and serum testosterone. As a 
marker of oxidative stress, urinary 8-hydroxy-2 ′  
-deoxyguanosine（8-OHdG）levels were evaluated 
using an ICR-001 device（Techno Medica, Yokohama, 
Japan）according to the manufacturer’s recommenda-
tions.
The primary end-point was change in the mean 
IPSS scores. The secondary end-points were changes 
in the mean values of the following parameters：（1）
Qmax and PVR,（2）number of micturations per night 
and hours of undisturbed sleep（HUS）, （3）IIEF5 
score and serum testosterone, and（4）urinary 8- 
OHdG level. The patient’s QOL was assessed on the 
basis of the IPSS-QOL. HUS was designated as the 
time between falling asleep and first waking to void.
Safety of treatment was assessed in terms of the 
number and severity of adverse events, results of lab-
oratory tests, and values of vital parameters. Adverse 
events were investigated throughout the treatment 
period. Laboratory tests and measurement of vital 
signs were conducted before and the end of the 
12-week period（or at discontinuation）. Further, com-
plete blood count was obtained, and blood chemistry 
tests were performed for the following parameters：
serum levels of albumin, lactate dehydrogenase, alka-
line phosphatase, aspartate aminotransferase, alanine 
transaminase, total bilirubin, creatinine, urea nitrogen, 
sodium, potassium, and chlorine. Urinalysis was per-
formed at every visit.
Data were reported as mean±SD and were ana-
lyzed using SPSS software version 12.0（IBM, Chicago, 
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IL USA）. Wilcoxon signed-rank test was used to eval-
uate the effects of treatment. P＜0.05 was considered 
significant.
???????
Baseline patient profile
The total number of patients enrolled in the study 
was 30. Of these, 25 patients（83.3％）completed the 
study and 5 patients（16.7％）dropped out because of 
adverse events. The baseline clinical characteristics of 
the patients are shown in Table 1.
Efficacy
After the 12-week treatment periods, there were 
significant improvements in lower urinary tract symp-
toms, as indicated by change in the mean IPSS scores 
in terms of total score（P＜0.001）, storage subscore（P
＝0.001）, voiding subscore（P＜0.001）, and QOL（P＝
0.002）；the mean Qmax and PVR did not significantly 
change（Table 2）. The FVC showed significant 
improvements in HUS（P＝0.006）, nocturnal polyuria 
index（NPI, P＝0.001）, and mean number of mictura-
tions per night（P＝0.012）, not in the mean number of 
micturitions per day.
There were no significant improvements in sexual 
function, as indicated by the change in the mean 
IIEF5 score and serum testosterone level. Likewise, 
oxidative stress, which was assessed by the urine 
8-OHdG levels, showed no improvement.
Safety
Among the 30 patients exposed to the study drug, 
5（16.7％）dropped out because of adverse events：2 
had a headache, 2 had dizziness and 1 had dyspepsia. 
There was no serious adverse event reported during 
the study and there was no evidence of hypotension 
or syncope during the treatment period. The results 
of blood biochemistry and urinalysis remained 
unchanged after 12 weeks（data not shown）.
??????????
This study showed significant improvement in the 
mean number of nocturia per night in FVC. The aim 
of our study was to evaluate whether tadalafil add-on 
treatment was effective for patients with BPH/LUTS 
and ED that showed resistance to a 1-blockers. 
Tadalafil, a selective cyclic guanosine monophosphate 
PDE5i, was approved by the US Food and Drug 
Administration for ED in 2003 for on demand use at 
10-20 mg and, in 2008 for once daily use at 2 .5 to 
5.0 mg；in 2011, it was approved for once daily use at 
5 mg for BPH/LUTS11）. Improvement in BPH/LUTS 
was evident from in 4 pivotal randomized, double-
blind, placebo controlled studies that reported a signif-
icantly greater mean change in total IPSS from base-
line to week 12 10,12〜14）.
The rat ionale for using a combination of an 
a1-blocker and a PDE5i was based on the following 
findings. First, it is well established that BPH/LUTS 
and ED are highly prevalent in aging men and are 
strongly linked independent of age and cardiovascular 
comorbidities；this link has biologic plausibility 15,16）. 
Also, a combination of an a1-blocker and a PDE5i 
???????　 Baseline clinical characteristics of patients with 
BPH/LUTS and ED（N＝30）
Age（years）　 Mean（SD） 
Range
71.3±8.5
58-80
Weight（kg）　 Mean（SD） 
Range
57.3±10.2
49.2-88.3
Alpha-1 blockers, n（％）　 Tamsulosin 
Naftopidil
19（63.3）
11（26.7）
IPSS　 Total score 
Storage subscore 
Voiding subscore 
QOL
15.6±5.7
6.9±3.2
8.7±4.3
4.3±1.3
IIEF5 5.5±6.5
UFM　 PVR（ml） 
Qmax（ml/s） 
Voided volume（ml）
27±18
9.0±5.8
154±101
Serum Testosterone（ng/ml） 5.5±2.1
Urinary 8-OHdG（ng/ml CRE） 23.5±12.9
BPH/LUTS, lower urinary tract symptoms suggestive of 
benign prostatic hyperplasia；
CRE, creatinine；
ED, erectile dysfunction；
IPSS, International Prostate Symptom Score；
IIEF5, International Index of Erectile Function of Erectile 
Function Domain；
UFM, uroflowmetry；
PVR, post-void residual urine；
Qmax, maximum urinary flow rate；
QOL, quality of life；
SD, standard deviation；
8-OHdG, 8-hydroxy-2′-deoxyguanosine
Hiroshi Yagi20 DJMS
acts on common urogenital target organs by two dif-
ferent mechanisms of action. Blockage of a-adrenear-
gic receptors and reduction of penile smooth muscle 
and prostate/bladder neck sympathetic tone could 
enhance the nitric oxide-mediated relaxant influence 
of PDE5i on the same smooth muscle targets 17）. A 
potentiating action of these two drugs is supported by 
preclinical and clinical findings. Indeed, in spontane-
ously hypertensive rats, a1-blocker alfuzosin showed 
no pro-erectile effect in itself, but enhanced the num-
ber and amplitude of erections induced by PDE5i apo-
morphine 18）. In a randomized study of ED patients 
who failed to respond to PDE5 i, addition of an 
a1-blocker was associated with a significant improve-
ment in IIEF5 in a majority（78.4％）, compared with 
those who received a placebo 19）. Similarly, in a retro-
spective analysis of men with ED and who were con-
sidered non-responders to PDE5i, addition of an 
a 1-blocker was shown to improve ED in 71％ of 
patients 20）. However, efficacy of PDE5i tadalafil as an 
add-on treatment for men with BPH/LUTS refractory 
to an a1-blocker has been not reported to date.
Frequent nighttime voiding episodes have been 
associated with increased risk of falls, fractures, sleep 
deprivation, and chronic fatigue, especially in older 
patients 21）. Nocturia is common in patients with heart, 
lung, kidney, bladder, or prostate problems, as well as 
in many other diseases, both urologic and non-urolog-
ic in origin. Polydipsia, use of diuretics in the evening, 
and fluid overload before sleeping are other reasons 
for nocturia 22）. Though nocturia is frequently reported 
by pat ients with BPH/LUTS, treatment with 
a 1-blockers generally has low efficacy 21）. On the 
other hand, a statistically significant improvement in 
nocturnal frequency was seen with tadalafil over pla-
cebo；however, the treatment difference was small 
and not considered clinically meaningful 23）. Limitations 
of our study to assess nocturia were not to exclude 
???????　Change in parameters after add-on treatment with tadalafil
Baseline 12 Weeks P-value
IPSS　 Total score 
Storage subscore 
Voiding subscore 
QOL
15.6±5.7
6.9±3.2
8.7±4.3
4.3±1.3
9.3±4.7
4.5±2.9
4.8±2.7
7.1±6.5
＜0.001
0.001
＜0.001
0.002
IIEF5 5.5±6.5 7.1±6.5 0.191
UFM　 voided volume（ml） 
PVR（ml） 
Qmax（ml/s）
154±101
27±18
9.0±5.8
191±93
39±35
10.4±7.3
0.257
0.180
0.330
FVC
　　　Number of micturitions per day
　　　Number of nocturia per night
　　　NPI
　　　HUS（hours）
11.1±4.0
2.9±1.5
0.39±0.14
2.5±1.1
9.9±3.1
2.1±1.2
0.29±0.12
3.4±1.7
0.154
0.024
0.002
0.026
Serum testosterone（ng/ml） 5.5±2.1 5.8±2.3 0.130
Urinary 8-OHdG（ng/ml CRE） 23.5±12.9 23.2±12.7 0.129
IPSS, International Prostate Symptom Score；
IIEF5, International Index of Erectile Function of Erectile Function Domain；
UFM, uroflowmetry；
PVR, post-void residual urine；
Qmax, maximum urinary flow rate；
FVC, frequency volume chart；
NPI, nocturnal polyuria index；
（ratio of nocturnal urine volume to 24 hour urine volume）；
HUS, hours of undisturbed sleep；
（time between falling asleep and first waking to void）；
8-OHdG, 8-hydroxy-2′-deoxyguanosine
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certain co-morbidities such as nocturnal polyuria. 
Whether tadalafil might show a greater effect on 
nighttime voiding frequency in studies specifically 
designed to assess nocturia remains unknown. If the 
impact of tadalafil on nocturia is to be assessed specifi-
cally in future studies, they should incorporate 
detailed patient history and frequency-volume charts.
HUS is considered as an important indicator of 
sleep quality and is a useful parameter for evaluating 
sleep disorders due to nocturia 24）. Sleep has two main 
phases：rapid eye movement（REM）sleep and non-
REM sleep 24）. Non-REM sleep normally comprises 
deep and shallow sleep phase and deep one is impor-
tant for growth hormone secretion and functional res-
toration 25）. Slow-wave sleep is a deep and restorative 
non-REM sleep that occurs within approximately 3 to 
4 hours of falling asleep, after which REM sleep and 
other shallow sleep stages become more promi-
nent 25,26）. Interruption of this restorative non-REM 
sleep can significantly impair sleep quality, causing 
general fatigue and discomfort. Djavan et al. reported 
that prolonging early undisturbed sleep may be effec-
tive for improving sleep quality 27）. The results of the 
present study showed that HUS was prolonged by an 
average of 54 minutes, which meant that early sleep 
was also significantly prolonged. Prolongation of early 
sleep is thought to have a positive influence on sleep 
quality and may have contributed to the improvement 
of IPSS-QOL.
Oxidative stress was reported to result in patho-
physiologic conditions of the urinary bladder due to 
damage to the urothelium and the sensitizing bladder 
afferent signals 28）. Previous studies have shown that 
oxidative stress mediated capsaicin-sensitive C-fibers 
to induce bladder hyperactivity 29）. Several investiga-
tors have shown that PDE5i enhanced the antioxidant 
system and scavenged free radicals 30）. Therefore, we 
hypothesized that PDE5i might ameliorate the patho-
physiologic conditions in the urinary bladder because 
of its anti-oxidant activity and could be a supplemen-
tary therapy for patients with BPH/LUTS and ED 
that are unresponsive to a1-blockers. However, in the 
present study, no significant improvement was 
observed in the urine 8-OHdG level.
The major drawbacks of this study are the small 
number of patients, the lack of a placebo controlled 
group, and the absence of urodynamic data. In LUTS 
conditions that have a strong placebo component, the 
possibility of a placebo effect might be high. There-
fore, the value of once daily add-on tadalafil as a 
potential therapeutic alternative in patients with 
a1-blocker resistant BPH/LUTS and ED needs to be 
evaluated prospectively in the future.
???????????
Once daily add-on administration of tadalafil in 
patients with BPH/LUTS and ED that are resistant to 
a1-blocker alleviated lower urinary tract symptoms 
and prolonged HUS, which is an indicator of sleep 
quality. Therefore, we recommend the use of tadalafil 
in patients with BPH/LUTS and ED that are resistant 
to a1-blockers and associated sleep disturbances.
???????????????????????????
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